Muraglitazar - CAS 331741-94-7
Catalog number:
331741-94-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H28N2O7
Molecular Weight:
516.54
COA:
Inquire
Targets:
PPAR
Description:
Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
Off-White Solid
Synonyms:
BMS 298585;N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine;Muraglitazar;N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine;Pargluva
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
A peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist.
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Melting Point:
123-125 °C
InChIKey:
IRLWJILLXJGJTD-UHFFFAOYSA-N
InChI:
1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
Canonical SMILES:
c1c(cccc1)c1oc(c(n1)CCOc1ccc(CN(C(=O)Oc2ccc(cc2)OC)CC(=O)O)cc1)C
Current Developer:
Bristol-Myers Squibb
1.Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.
Paukkeri EL, Leppänen T, Lindholm M, Yam MF, Asmawi MZ, Kolmonen A, Aulaskari PH, Moilanen E. Arthritis Res Ther. 2013 Apr 17;15(2):R51. doi: 10.1186/ar4211.
INTRODUCTION: Peroxisome proliferator-activated receptor (PPAR) agonists are widely used drugs in the treatment of diabetes and dyslipidemia. In addition to their metabolic effects, PPAR isoforms PPARα and PPARγ are also involved in the regulation of immune responses and inflammation. In the present study, we investigated the effects of a dual PPARγ/α agonist muraglitazar on inflammatory gene expression in activated macrophages and on carrageenan-induced inflammation in the mouse.
2.PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A1, Anthérieu S2, Vluggens A2, Umbdenstock T3, Claude N4, de la Moureyre-Spire C5, Weaver RJ5, Guillouzo A6. Toxicol Appl Pharmacol. 2014 Apr 1;276(1):73-81. doi: 10.1016/j.taap.2014.02.001. Epub 2014 Feb 15.
Although non-alcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease there is no pharmacological agent approved for its treatment. Since peroxisome proliferator-activated receptors (PPARs) are closely associated with hepatic lipid metabolism, they seem to play important roles in NAFLD. However, the effects of PPAR agonists on steatosis that is a common pathology associated with NAFLD, remain largely controversial. In this study, the effects of various PPAR agonists, i.e. fenofibrate, bezafibrate, troglitazone, rosiglitazone, muraglitazar and tesaglitazar on oleic acid-induced steatotic HepaRG cells were investigated after a single 24-hour or 2-week repeat treatment. Lipid vesicles stained by Oil-Red O and triglycerides accumulation caused by oleic acid overload, were decreased, by up to 50%, while fatty acid oxidation was induced after 2-week co-treatment with PPAR agonists. The greatest effects on reduction of steatosis were obtained with the dual PPARα/γ agonist muraglitazar.
3.Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries.
Uurto I1, Hämäläinen M2, Suominen V3, Laurila M4, Kotsar A3, Isotalo T5, Tammela TL3, Kellomäki M6, Salenius JP3. J Vasc Interv Radiol. 2015 Jan;26(1):124-30. doi: 10.1016/j.jvir.2014.10.005. Epub 2014 Nov 18.
PURPOSE: To evaluate the biocompatibility of a new muraglitazar-eluting polylactide copolymer stent and investigate its ability to prevent the formation of intimal hyperplasia.
4.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.
Tseng CH1, Tseng FH. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519.
This article reviews available animal studies on the possible link between the use of peroxisome proliferator-activated receptor (PPAR) agonists and bladder cancer, with further discussion on the possible implications to humans. Carcinogenicity studies suggest that the PPARγ agonist pioglitazone and dual PPARα/γ agonists such as ragaglitazar, muraglitazar, and naveglitazar may increase the risk of bladder cancer in a dose-responsive pattern in rats. It is interesting that bladder cancer related to PPAR agonists shows remarkable species- and sex-specificity and has a predilection to occur in the ventral dome of bladder in rodents. While male rats treated with pioglitazone or muraglitazar have a higher propensity to develop bladder cancer than female rats, mice of both sexes do not develop bladder cancer even when exposed to very high doses. Direct genotoxicity or cytotoxicity of PPAR agonists is unlikely to be the mode of action because most of the parent compounds or their metabolites of the PPAR agonists are neither mutagenic nor genotoxic, and they are rarely excreted in the urine; but a receptor-mediated PPAR effect cannot be excluded.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products


CAS 223132-38-5 Inolitazone dihydrochloride

Inolitazone dihydrochloride
(CAS: 223132-38-5)

In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude ...

CAS 1000998-59-3 BMS-687453

BMS-687453
(CAS: 1000998-59-3)

BMS-687453 is a potent and selective peroxisome proliferator activated receptor PPARα agonist. with an IC50 of 10 nM for human PPARalpha and approximately 410-f...

CAS 108409-83-2 FH535

FH535
(CAS: 108409-83-2)

FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.

CAS 1014691-61-2 GSK0660

GSK0660
(CAS: 1014691-61-2)

GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...

CAS 476436-68-7 Naveglitazar

Naveglitazar
(CAS: 476436-68-7)

Naveglitazar is a Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist

CAS 539813-69-9 PPAR agonist 1

PPAR agonist 1
(CAS: 539813-69-9)

An agonist of PPAR α and PPAR γ

CAS 97322-87-7 Troglitazone

Troglitazone
(CAS: 97322-87-7)

Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...

SR 1664
(CAS: 1338259-05-4)

SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...

CAS 425671-29-0 LY-518674

LY-518674
(CAS: 425671-29-0)

LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...

CAS 161600-01-7 MCC-555

MCC-555
(CAS: 161600-01-7)

MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...

CAS 112529-15-4 Pioglitazone HCl

Pioglitazone HCl
(CAS: 112529-15-4)

Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes inhibitor for CYP2C8, CYP3A4 and CYP2C9 wit...

CAS 1639792-20-3 Saroglitazar (Magnesium)

Saroglitazar (Magnesium)
(CAS: 1639792-20-3)

Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...

CAS 223132-37-4 Inolitazone

Inolitazone
(CAS: 223132-37-4)

Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...

INT 131
(CAS: 315224-26-1)

INT 131 is a hypoglycemic agent, displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared...

PT-S58
(CAS: 1356497-92-1)

PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...

CAS 863405-60-1 JW74

JW74
(CAS: 863405-60-1)

JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...

CAS 188591-46-0 GSK-3787

GSK-3787
(CAS: 188591-46-0)

GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.

CAS 637-07-0 Clofibrate

Clofibrate
(CAS: 637-07-0)

Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

Seladelpar
(CAS: 851528-79-5)

Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...

Imiglitazar
(CAS: 250601-04-8)

Imiglitazar, also known as TAK-559,with hypoglycemic activity it is a non-thiazolidinedione dual peroxisome proliferator-activated receptor (PPAR) alpha and gam...

Chemical Structure

CAS 331741-94-7 Muraglitazar

Quick Inquiry

Verification code

Featured Items